← Back to Screener
Annovis Bio, Inc. (ANVS)
Price$1.78
Favorite Metrics
Price vs S&P 500 (26W)-26.45%
Price vs S&P 500 (4W)-34.57%
Market Capitalization$60.78M
All Metrics
Book Value / Share (Quarterly)$0.62
P/TBV (Annual)2.36x
Cash Flow / Share (Quarterly)$-0.94
Price vs S&P 500 (YTD)-51.78%
EPS (TTM)$-1.39
10-Day Avg Trading Volume1.82M
EPS Excl Extra (TTM)$-1.39
EPS (Annual)$-1.40
ROI (Annual)-171.23%
Cash / Share (Quarterly)$0.72
ROA (Last FY)-136.87%
EBITD / Share (TTM)$-1.44
ROE (5Y Avg)-125.97%
Cash Flow / Share (Annual)$-0.94
P/B Ratio3.61x
P/B Ratio (Quarterly)5.44x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-7.25x
ROA (TTM)-133.49%
EPS Incl Extra (Annual)$-1.40
Current Ratio (Annual)5.80x
Quick Ratio (Quarterly)5.37x
3-Month Avg Trading Volume0.63M
52-Week Price Return41.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.74
52-Week High$5.50
EPS Excl Extra (Annual)$-1.40
26-Week Price Return-22.47%
Quick Ratio (Annual)5.37x
13-Week Price Return-48.99%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.80x
Enterprise Value$41.245
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.72
3-Month Return Std Dev97.02%
Net Income / Employee (TTM)$-4
ROE (Last FY)-171.23%
Net Interest Coverage (Annual)-0.89x
EPS Basic Excl Extra (Annual)$-1.40
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.39
ROI (TTM)-159.43%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.47
Price vs S&P 500 (52W)12.11%
Year-to-Date Return-49.13%
5-Day Price Return8.64%
EPS Normalized (Annual)$-1.40
ROA (5Y Avg)-193.17%
Month-to-Date Return-21.08%
Cash Flow / Share (TTM)$-1.72
EBITD / Share (Annual)$-1.44
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-125.97%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.39
P/TBV (Quarterly)10.02x
P/B Ratio (Annual)5.44x
Book Value / Share (Annual)$0.62
Price vs S&P 500 (13W)-49.67%
Beta1.27x
Revenue / Share (TTM)$0.00
ROE (TTM)-159.43%
52-Week Low$1.19
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ANVSAnnovis Bio, Inc. | — | — | — | — | $1.78 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Annovis Bio is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, primarily Alzheimer's and Parkinson's disease. Its pipeline includes Buntanetap for chronic neurodegeneration, ANVS405 for acute neurodegeneration, and ANVS301 for Alzheimer's disease.